Methylene blue (review of toxicology, dosing and special risks) (2003)

Peer-Reviewed Study · Clifton J, Leikin JB · 2003

Clifton J et al., 2003: Clinical review of methylene blue as a methemoglobinemia antidote that names G6PD deficiency, aniline dye exposure and dapsone as the situations carrying special risk. It is the standard short statement of who is at risk.

People with G-6-PD deficiency, along with patients exposed to aniline dyes and dapsone, may present with special risks in the treatment of methemoglobinemia.

Clifton J et al., 2003: Clinical review of methylene blue as a methemoglobinemia antidote that names G6PD deficiency, aniline dye exposure and dapsone as the situations carrying special risk. It is the standard short statement of who is at risk. Study type: review.